Roberta Angelico
Overview
Explore the profile of Roberta Angelico including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
89
Citations
704
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Angelico R, Trapani S, Manzia T, Lenci I, Grossi P, Ricci A, et al.
Am J Transplant
. 2025 Mar;
PMID: 40057194
Patients with HDV/HBV-related end-stage liver disease candidates for liver transplantation(LT) have traditionally been regarded as a special population, although their outcomes are controversial. A intention-to-treat(ITT) analysis of long-term outcomes of...
2.
Angelico R, Levitsky J
Am J Transplant
. 2024 Dec;
25(3):461-462.
PMID: 39638045
No abstract available.
3.
Manzia T, Sensi B, Gentileschi P, Quaranta C, Toti L, Baiocchi L, et al.
Liver Transpl
. 2024 Oct;
PMID: 39451118
In obese patients, metabolic dysfunction-associated steatotic liver disease is becoming a leading etiology of end-stage liver disease and HCC. Simultaneous liver transplantation and sleeve gastrectomy (LT-SG) have been proposed in...
4.
Serenari M, Angelico R, Lai Q, Patrono D, Scalera I, Kauffmann E, et al.
Dig Liver Dis
. 2024 Oct;
57(2):459-466.
PMID: 39379228
Background: Availability of liver transplantation (LT) as a treatment for hepatocellular carcinoma (HCC) and other liver malignancies may determine heterogeneity of therapeutic strategies across different centers. Aims: To investigate the...
5.
Angelico R, Siragusa L, Blasi F, Bellato V, Mineccia M, Lolli E, et al.
Discov Oncol
. 2024 Oct;
15(1):529.
PMID: 39378005
Introduction: Patients with ulcerative colitis (UC) receiving liver transplantation (LT) due to primary sclerosing cholangitis (PSC) have higher risk of developing colorectal cancers (CRC). Aim of this systematic review was...
6.
Angelico R, Bonaccorsi Riani E, De Martin E, Parente A, Foguenne M, Sensi B, et al.
Liver Transpl
. 2024 Sep;
31(2):181-189.
PMID: 39347698
The evolving field of liver transplant (LT) oncology calls for tailored immunosuppression protocols to minimize the risk of tumor recurrence. We systematically reviewed the available evidence from inception to May...
7.
Toti L, Manzia T, Giuliano F, Picchi E, Tariciotti L, Pedini D, et al.
Clin Pract
. 2024 Sep;
14(5):1669-1681.
PMID: 39311283
Background: Intraductal papillary neoplasms of the bile duct (IPNB) are rare precancerous lesions with implications for the development of cholangiocarcinoma (CCA). Recognizing IPNB and managing its recurrence pose challenges in...
8.
Manzia T, Trapani S, Nardi A, Ricci A, Lenci I, Sensi B, et al.
Dig Liver Dis
. 2024 Sep;
57(2):408-416.
PMID: 39237429
Background: The challenge of transplant waiting-lists is to provide organs for all candidates while maintaining efficiency and equity. Aims: We investigated the probability of being transplanted or of waiting-list dropout...
9.
Sensi B, Angelico R, Toti L, Conte L, Coppola A, Tisone G, et al.
Curr Mol Pharmacol
. 2024 Sep;
17:e18761429310703.
PMID: 39225204
In the last decade, immunotherapy (IT) has revolutionized oncology and found indications in many cancers, including hepatocellular carcinoma (HCC). In HCC, IT has become the leading systemic therapy for advanced...
10.
Angelico R, Sensi B, Toti L, Campanella E, Lenci I, Baiocchi L, et al.
Transplantation
. 2024 May;
108(11):2247-2259.
PMID: 38771123
Background: Liver transplant (LT) recipients often experience adverse effects of immunosuppressive (IS) drugs, especially on metabolic profiles. Selected LT recipients can achieve successful IS withdrawal; however, its effects on metabolic...